Home › Kanser sa Bile
Pag-aaral pangklinika para sa Kanser sa Bile na nagre-recruit sa U.S.
14 pag-aaral para sa Kanser sa Bile ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Nashville, TN5 pag-aaral
- Baldwin Park, CA4 pag-aaral
- Houston, TX4 pag-aaral
- Boston, MA4 pag-aaral
- Dallas, TX3 pag-aaral
- Oklahoma City, OK3 pag-aaral
- New York City, NY3 pag-aaral
- Seattle, WA3 pag-aaral
- Cleveland, OH3 pag-aaral
- Louisville, KY3 pag-aaral
- Los Angeles, CA3 pag-aaral
- Pittsburgh, PA3 pag-aaral
- Birmingham, AL3 pag-aaral
- Miami, FL3 pag-aaral
- Philadelphia, PA3 pag-aaral
- Portland, OR3 pag-aaral
Ayos sa estado
- Alabama3 pag-aaral
- California9 pag-aaral
- Colorado5 pag-aaral
- Connecticut3 pag-aaral
- Florida9 pag-aaral
- Illinois4 pag-aaral
- Kentucky3 pag-aaral
- Massachusetts5 pag-aaral
- Minnesota3 pag-aaral
- New York4 pag-aaral
- North Carolina4 pag-aaral
- Ohio6 pag-aaral
- Oklahoma3 pag-aaral
- Oregon3 pag-aaral
- Pennsylvania4 pag-aaral
- Tennessee5 pag-aaral
- Texas6 pag-aaral
- Washington3 pag-aaral
- Wisconsin3 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Nagre-recruit
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT04907643Distance-Based Exercise to Preserve Function and Prevent Disability
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07059884A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06760819Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 28, 2026 · NCT06282575Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT06239194The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04585750A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07265674A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07221253DESTINY-PANTUMOUR04
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 130 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07124000Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT07780838Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05285358Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Nagre-recruitPhase 1/2
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT05000294Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT06101277Integrated Cancer Repository for Cancer Research
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.